Mastrolorenzo A, Tiradritti L, Salimbeni L, Zuccati G
Department of Dermatology, STD & AIDS Center, University of Florence, Italy.
Int J STD AIDS. 1995 Nov-Dec;6(6):431-5. doi: 10.1177/095646249500600611.
The aim of this work was to confirm our preliminary clinical and immunological evaluation of the protective effects of a herpes simplex virus (HSV) vaccine derived from killed virus in the treatment of relapsing facial or genital herpes simplex infection. A total of 142 patients were treated with the HSV vaccine and a control group of 50 were treated with intermittent oral acyclovir (ACV). The vaccine reduced annual active disease days in vaccinees to 11.59 (+/- 15.3) after treatment (65.11 +/- 31.64 before treatment) compared to 30.4 +/- 17.49 days after treatment of the control group patients (71.86 +/- 32.5 before treatment).
这项工作的目的是证实我们对一种由灭活病毒制成的单纯疱疹病毒（HSV）疫苗在治疗复发性面部或生殖器单纯疱疹感染中的保护作用所做的初步临床和免疫学评估。共有142名患者接受了HSV疫苗治疗，另有50名患者组成的对照组接受了间歇性口服阿昔洛韦（ACV）治疗。与对照组患者治疗后30.4±17.49天（治疗前71.86±32.5天）相比，疫苗使接种疫苗者治疗后的年发病天数降至11.59天（±15.3）（治疗前为65.11±31.64天）。
